Edoxaban (INN, codenamed DU-176b, trade name Lixiana) is a potent, selective factor Xa inhibitor, which has good oral bioavailability. Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is being developed by Daiichi Sankyo. It was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism.
Anon.Crystalline form of N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide. Volume 16. Issue 12A. Pages 1-2. (IP.com Journal)
Noguchi, Shigeru; Koyama, Takeo. Process for the preparation of oxadiazole compounds containing cyclohexanediamine moiety. WO 2008156159. (Assignee Daiichi Sankyo Company, Limited, Japan)
Kawanami, Koutarou. Method for the preparation of optically active diamine derivative. WO 2010104106. (Assignee Daiichi Sankyo Company,Limited, Japan)
Bodhuri, Prabhudas; Karadeolian, Avedis; Cammisa, Eduardo Gustavo; Green, Stuart P.; Green, Melanie R. A.; Ceccarelli, Alfredo Paul. Processes for the preparation of edoxaban intermediates and salts thereof. US 20180179226. (Assignee Apotex Inc., Can.)
Koyama, Takeo; Kondo, satoshi. Process for the preparation of diamine derivative. WO 2010104078. (Assignee Daiichi Sankyo Company,Limited, Japan)
Nakamura, Yoshitaka; Mukesh, Kumar Madhra; Inamdar, Murad Ismail. A process for the preparation of bromooxabicyclooctanone. WO 2014081047. (Assignee Daiichi Sankyo Company, Limited, Japan)
Nakamura, Yoshitaka; Michida, Makoto; Kaneda, Takeshi. Method for preparing optically active diamine derivatives. WO 2014157653. (Assignee Daiichi Sankyo Company Limited, Japan)
Takayanagi, Yoshihiro; Furuya, Yukito; Nakamura, Yoshitaka. Method for producing (1S,4S,5S)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one. WO 2014157612. (Assignee Daiichi Sankyo Company, Limited, Japan)
Ueda, Tsuyoshi. Preparation of activated blood coagulation factor X (FXa) inhibitor compounds under mild conditions. WO 2015125710. (Assignee Daiichi Sankyo Company,Limited, Japan)
Li, Ying; Wang, Qingpeng; Liu, Zhikang. Process for preparation of edoxaban free base. CN 105753888. (Assignee Lepu Pharmaceutical Co., Ltd., Peop. Rep. China)
